MIAMI, Sept. 20, 2016 /PRNewswire/ -- At their sold out September 2016 Bella's Ball in Miami, Live Like Bella® Childhood Cancer Foundation and Biomarck Pharmaceuticals announced a partnership to offer Biomarck's patented compound Bio-11006 as an option for compassionate use in children battling certain types of cancer. Biomarck is a biopharmaceutical company with a patented technology platform which utilizes anti-MARCKS peptides to develop and license products targeted to treat diseases.
Live Like Bella® and Biomarck have partnered to offer compassionate use of it's new developmental compound to children with certain types of cancers potentially as early as 1st quarter of 2017. While Bio-11006 has only been shown to have effectiveness in human cell cultures and animals in the laboratory, it has demonstrated impressive results in adult tumors and childhood cancers, specifically, Rhabdomyosarcoma, Neuroblastoma and Osteosarcoma in children. These cancers have high mortality rates in children and the potential opportunity of a new treatment is encouraging to physicians who treat children with cancer. Dr. Guillermo De Angulo, Pediatric Oncologist joined in making this major announcement: 'There's nothing more difficult than having to look at parents in the eye and tell them, I'm sorry, there's nothing more we can do. The promise of a potential new treatment option for compassionate use in children is promising and very much needed.'
Joining Raymond Rodriguez-Torres, chairman of Live Like Bella® and Dr. De Angulo on stage for the announcement was Rajin Ahuja, Chairman of the Board of Biomarck, Dr. Brian Dickson, CEO, and Dr. Ken Adler, inventor of Bio-11006.
"We are thrilled to be here and to announce this partnership with Live Like Bella® in support of the fight against childhood cancer," said Rajin Ahuja, Chairman of Biomarck. Per Dr. Dickson, CEO, the product is expected to be available in early 2017 and while not all cases will be eligible for compassionate use, the company does intend to help as much as it can with free drug for cases that qualify and have not responded to current approved treatment. Bio-11006 has been demonstrated to be safe and tolerable in roughly 200 adult humans that have taken the drug in previous studies for lung diseases.
Bio-11006 expects to receive FDA approval to commence human trials in adult lung cancer, which will begin 2017. In the interim Biomarck plans to offer the drug under the compassionate use program to pediatric cancer patients with help from Live Like Bella®. Currently, Bio-11006 is administered via nebulizer and promises to be easy to take particularly for children who normally receive cancer treatment intravenously.
LIVE LIKE BELLA®
Live Like Bella® founded in June 2013 in memory of Bella Rodriguez-Torres, who passed away at the tender age of 10 from Rhabdomyosarcoma, an aggressive childhood cancer. In her six-year battle she inspired millions to #LiveLikeBella and we are dedicated to finding a cure for pediatric cancer by funding innovative pediatric cancer research. Our Foundation also provides support for families with children currently in treatment and assists families who have lost a child to cancer with funeral or headstone expenses. For information visit www.LiveLikeBella.org
BIOMARCK PHARMACEUTICALS LIMITED
Biomarck Pharmaceuticals Limited is a NC biopharma company focused on developing products for serious diseases such as lung cancer and acute respiratory distress syndrome (ARDS). In conjunction with North Carolina State University and Live Like Bella®, Biomarck is delighted to support a compassionate use program in children with cancers who are not responding to approved therapy.
For information visit www.biomarck.com
Jessica de Quesada
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/live-like-bella--biomarck-pharmaceuticals-launch-partnership-to-offer-innovative-inhaled-medication-to-children-battling-cancer-300330674.html
SOURCE Live Like Bella